论文部分内容阅读
目的研究5α还原酶抑制剂对前列腺体积≥30 mL前列腺增生患者的治疗效果。方法将我院泌尿外科2016年1月—2017年1月住院、门诊200例前列腺体积≥30 mL前列腺增生患者随机分为2组,对照组:盐酸坦洛新缓释胶囊0.2 mg口服,每天1次;治疗组:非那雄胺5 mg口服qd,盐酸坦洛新缓释胶囊0.2 mg口服,每天1次。2组用药6个月后,根据最大尿流率(mL/s)、前列腺体积(mL)、残余尿量(mL)、I-PSS评分评定疗效。结果治疗组和对照组患者最大尿流率均较治疗前提高,前列腺体积、残余尿、I-PSS评分均较治疗前降低,且治疗组的改善幅度优于对照组,差异有统计学意义(P<0.05)。结论 5α还原酶抑制剂对前列腺体积≥30mL前列腺增生患者的治疗有明显效果。
Objective To investigate the therapeutic effect of 5α reductase inhibitor on prostatic hyperplasia in patients with prostate volume ≥30 mL. Methods Urine surgery from January 2016 to January 2017 in our hospital was performed in 200 outpatients with benign prostatic hyperplasia ≥30 mL. Patients in control group were given 0.2 mg tamsulosin hydrochloride sustained release capsules orally daily Times; treatment group: finasteride 5 mg oral qd, tamsulosin hydrochloride sustained release capsules 0.2 mg orally, once daily. After 6 months of treatment, the effects of maximum flow rate (mL / s), prostate volume (mL), residual urine volume (mL) and I-PSS score were evaluated. Results The maximum urinary flow rate in treatment group and control group was higher than that before treatment. Prostatic volume, residual urine and I-PSS score were lower than those before treatment, and the improvement rate of treatment group was better than that of control group P <0.05). Conclusions 5α reductase inhibitors have a significant effect on the treatment of prostatic hyperplasia in patients with prostate volume ≥30mL.